RenovoRx Correlations
RNXT Stock | USD 1.12 0.07 5.88% |
The current 90-days correlation between RenovoRx and Kiora Pharmaceuticals is 0.15 (i.e., Average diversification). The correlation of RenovoRx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
RenovoRx Correlation With Market
Significant diversification
The correlation between RenovoRx and DJI is 0.09 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding RenovoRx and DJI in the same portfolio, assuming nothing else is changed.
RenovoRx |
Moving against RenovoRx Stock
0.5 | BMEA | Biomea Fusion | PairCorr |
0.48 | KALV | Kalvista Pharmaceuticals | PairCorr |
0.44 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
0.43 | PALI | Palisade Bio | PairCorr |
0.42 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.4 | INZY | Inozyme Pharma | PairCorr |
0.35 | KTTA | Pasithea Therapeutics | PairCorr |
0.35 | NTRB | Nutriband | PairCorr |
0.32 | PBCRY | Bank Central Asia | PairCorr |
0.32 | KO | Coca Cola Aggressive Push | PairCorr |
0.31 | TLKMF | Telkom Indonesia Tbk | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between RenovoRx Stock performing well and RenovoRx Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze RenovoRx's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
KPRX | 2.77 | (0.29) | 0.00 | (0.26) | 0.00 | 5.95 | 16.59 | |||
ZVSA | 4.67 | (0.99) | 0.00 | 0.60 | 0.00 | 9.17 | 78.93 | |||
SONN | 4.76 | (0.77) | 0.00 | 2.19 | 0.00 | 12.31 | 37.58 | |||
ZURA | 3.78 | (0.36) | 0.00 | (0.09) | 0.00 | 7.95 | 30.69 | |||
PHIO | 4.53 | (0.30) | 0.00 | (0.18) | 0.00 | 11.78 | 36.22 | |||
RNAZ | 7.63 | 1.05 | 0.10 | (0.44) | 6.52 | 22.00 | 68.80 | |||
QNRX | 6.21 | 0.47 | 0.07 | 0.37 | 6.73 | 17.65 | 74.46 |
RenovoRx Corporate Management
CGMA CPA | Controller VP | Profile | |
Ronald CPA | VP Controller | Profile | |
James Ahlers | Chief Officer | Profile | |
Leesa Gentry | Senior Operations | Profile | |
Angela Nelms | Chief Officer | Profile | |
Ryan Witt | Senior Partnerships | Profile | |
Ramtin MD | Chairman Founder | Profile |